NUWE vs. NXGL, DRIO, CODX, PTHL, NRXS, NEPH, LFWD, PETV, BSGM, and ALUR
Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include NEXGEL (NXGL), DarioHealth (DRIO), Co-Diagnostics (CODX), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), NeurAxis (NRXS), Nephros (NEPH), ReWalk Robotics (LFWD), PetVivo (PETV), BioSig Technologies (BSGM), and Allurion Technologies (ALUR). These companies are all part of the "medical equipment" industry.
Nuwellis vs.
Nuwellis (NASDAQ:NUWE) and NEXGEL (NASDAQ:NXGL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, community ranking, profitability, dividends and earnings.
NEXGEL has lower revenue, but higher earnings than Nuwellis. NEXGEL is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
NEXGEL has a net margin of -52.60% compared to Nuwellis' net margin of -169.54%. NEXGEL's return on equity of -71.19% beat Nuwellis' return on equity.
3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 2.2% of NEXGEL shares are owned by institutional investors. 2.6% of Nuwellis shares are owned by insiders. Comparatively, 24.9% of NEXGEL shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Nuwellis has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, NEXGEL has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.
In the previous week, NEXGEL had 2 more articles in the media than Nuwellis. MarketBeat recorded 5 mentions for NEXGEL and 3 mentions for Nuwellis. Nuwellis' average media sentiment score of -0.08 beat NEXGEL's score of -0.40 indicating that Nuwellis is being referred to more favorably in the media.
Nuwellis received 21 more outperform votes than NEXGEL when rated by MarketBeat users. Likewise, 53.66% of users gave Nuwellis an outperform vote while only 50.00% of users gave NEXGEL an outperform vote.
Nuwellis presently has a consensus price target of $17.00, suggesting a potential upside of 1,197.71%. Given Nuwellis' stronger consensus rating and higher possible upside, research analysts clearly believe Nuwellis is more favorable than NEXGEL.
Summary
Nuwellis beats NEXGEL on 10 of the 19 factors compared between the two stocks.
Get Nuwellis News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUWE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Nuwellis Competitors List
Related Companies and Tools
This page (NASDAQ:NUWE) was last updated on 2/18/2025 by MarketBeat.com Staff